Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Non-Current Deffered Revenue (2020 - 2023)

TriSalus Life Sciences has reported Non-Current Deffered Revenue over the past 3 years, most recently at $8.8 million for Q2 2023.

  • For Q2 2023, Non-Current Deffered Revenue changed 0.0% year-over-year to $8.8 million; the TTM value through Jun 2023 reached $8.8 million, changed 0.0%, while the annual FY2022 figure was $8.8 million, 0.0% changed from the prior year.
  • Non-Current Deffered Revenue for Q2 2023 was $8.8 million at TriSalus Life Sciences, roughly flat from $8.8 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $8.8 million in Q4 2021 and troughed at $8.8 million in Q4 2021.
  • A 3-year average of $8.8 million and a median of $8.8 million in 2021 define the central range for Non-Current Deffered Revenue.
  • On a YoY basis, Non-Current Deffered Revenue climbed as much as 0.0% in 2022 and fell as far as 0.0% in 2022.
  • Year by year, Non-Current Deffered Revenue stood at $8.8 million in 2021, then changed by 0.0% to $8.8 million in 2022, then changed by 0.0% to $8.8 million in 2023.
  • Business Quant data shows Non-Current Deffered Revenue for TLSI at $8.8 million in Q2 2023, $8.8 million in Q1 2023, and $8.8 million in Q4 2022.